Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,798 people get CTIC articles and Market Currents by email alert.
Get email alerts on CTIC »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Mon, 1:30AM)
-
PR Newswire (May 15, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
PR Newswire (Mar 28, 2013)
-
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 28, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
More Drama From Cell TherapeuticsM. E. Garza • Mon, Jan 30, 2012 -
-
-
-
-
Cell Therapeutics: FDA Approves Italian FactoryZacks Investment Research • Tue, Mar 9, 2010
-
-
-
-
-
-
Cell Therapeutics Starts Phase III Lung Cancer TrialSA Editor Susan Lerner • Mon, Sep 24, 2007
-
-
-
-
-
-
-
-
-
Today's Market News To Trade On: 5 Stocks Moving On NewsMatthew Smith • Wed, Sep 12, 2012 -
-
-
-
-
-
-
-
-
-
-
-
Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)Fri, Aug 31, 2012
-
Cell Therapeutics, Inc. Q1 2010 Earnings Call TranscriptWed, Apr 28, 2010
-
Cell Therapeutics, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 18, 2008
-
PR Newswire (Mon, 1:30AM)
-
PR Newswire (May 15, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
PR Newswire (Mar 28, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Dec 10, 2012)
-
PR Newswire (Nov 12, 2012)
-
PR Newswire (Nov 12, 2012)
CTIC vs. ETF Alternatives
Company Description
We develop, acquire and commercialize novel treatments for cancer. Our goal is to build a leading biopharmaceutical company with a diversified portfolio of proprietary cancer drugs. Our research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 2:21 PM Shares of Cell Therapeutics (CTIC +6.5%) spike higher ahead of today's upcoming presentation at the UBS Global Healthcare Conference. The presentation will be held at 2:30 ET and is accessible on webcast here: [[CTIC} Presentation Webcast}. Comment! [Healthcare, On the Move]
-
Monday, May 6, 9:12 AM
Premarket gainers: CBMX +8%. YRCW +7%. APO +7%. CTIC +6%.
Losers: PAL -12%. LNCO -7%. LINE -6%. 12 Comments [On the Move] - Thursday, March 28, 11:06 AM Cell Therapeutics (CTIC +12.5%) trades higher today after securing a loan agreement with Hercules Technology Growth Capital for a senior secured term loan of up to $15M. The proceeds are intended to provide additional operating capital to advance Phase 3 clinical studies of pacritinib, its treatment for patients with myelofibrosis, and driving the adoption of Pixuvri in Europe . 1 Comment [Healthcare, On the Move]
-
Thursday, March 28, 9:10 AM
Premarket gainers: RPRX +75%. CTIC +14%. ONCY +8%. EXM +7%. DECK +6%. XONE +6%.
Losers: TWO -8%. FIVE -7%. GME -5%. 1 Comment [On the Move] -
Tuesday, March 26, 9:15 AM
Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move] - Monday, March 4, 6:21 AM Cell Therapeutics' (CTIC) and Chroma Therapeutics' tosedostat drug performs well in a Phase II trial of elderly patients with relapsed or refractory acute myeloid leukemia, with the once-daily oral treatment achieving a disease-control rate of 51%. (PR) Comment! [Healthcare]
- Thursday, February 28, 5:47 PM Cell Therapeutics (CTIC): Q4 EPS of -$0.20 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, January 31, 2:33 PM Cell Therapeutics (CTIC -0.7%) says the Gynecologic Oncology Group has informed it that an independent Data Safety Monitoring Board has recommended the continuation of Phase 3 clinical trials of Opaxiotm, a therapy for ovarian cancer, with no changes following a planned interim survival analysis. 2 Comments [Healthcare]
- Wednesday, January 9, 2:24 PM After rising nearly 25% yesterday on big volume, shares of Cell Therapeutics (CTIC -11%) give back a big chunk today. The stock has been volatile over the past few sessions, largely trading in tandem with big moves in competitor Peregrine Pharmaceuticals (PPHM -11%), who announced favorable news on Mondary of its review of data on its experimental cancer drug bavituximab, saying it wasn't comprimised. 1 Comment [Healthcare, On the Move]
-
Wednesday, January 9, 12:45 PM
Midday top 10 gainers: ININ +19%. KGJI +15%. SINO +14%. ZIPR +14%. CTC +14%. ROSG +13%. CSIQ +13%. TSL +13%. SAAS +12%. SMED +12%.
Midday top 10 Losers: SCHS -29%. PPHM -12%. PTEK -11%. CTIC -11%. DLGC -11%. MG -11%. ZA -10%. DYSL -9%. APOL -9%. CRK -8%. Comment! [On the Move] - Tuesday, January 8, 10:10 AM Cell Therapeutics (CTIC) rockets 24%, although it's hard to work out why. The stock's been fairly volatile over the past few months, and often seems to receive a big lift on news of Pixuvri, its treatment of aggressive non-Hodgkin B-cell lymphomas. 3 Comments [On the Move, Healthcare]
-
Tuesday, January 8, 9:10 AM
Premarket gainers: PERI +19%. STSI +16%. CTIC +8%. PPHM +5%.
Losers: GME -10%. APPY -6%. CY -6%. CLMT -5%. Comment! [On the Move] - Monday, December 17, 2012, 3:47 PM Cell Therapeutics (CTIC +2.8%) moves higher today after publishing positive results from a pre-clinical study of Pixuvri in The Journal of Pharmacology and Experimental Therapeutics. The study showed that in a human cardiac tissue model treated with Pixuvri did not form reactive oxygen species or long lived hydroxymetabolites. Additionally, the drug inhibited formation of the long-lived hydroxymetabolite of doxorubicin, which suggests a low incidence of cardiotoxicity. Comment! [Healthcare, On the Move]
-
Monday, December 17, 2012, 9:10 AM
Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
Losers: NBG -13%. CLWR -11%. SQNM -6%. Comment! [On the Move] - Monday, December 10, 2012, 3:24 PM Cell Therapeutics (CTIC -5.9%) dips today after its Board of Directors approves amendments to CTI's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights from $14.00 to $8.00 and to extend the final expiration date from January 7, 2010, to December 3, 2015. The Rights were initially distributed as a dividend on CTI's common stock. 1 Comment [Healthcare, On the Move]
-
Monday, October 15, 2012, 9:10 AM
Premarket gainers: YONG +15%. CLWR +14%. EDU +14%. AEGR +14%. CEL +9%. MTSL +8%. CTIC +8%. ISIS +7%.
Losers: DCTH -12%. 1 Comment [On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.